Skip to main content
Crossject logo

Crossject — Investor Relations & Filings

Ticker · ALCJ ISIN · FR0011716265 LEI · 969500W1VTFNL2D85A65 PA Manufacturing
Filings indexed 353 across all filing types
Latest filing 2026-04-30 Annual Report
Country FR France
Listing PA ALCJ

Crossject is a specialty pharmaceutical company focused on developing and commercializing medications for life-threatening emergency situations. The company's core technology is ZENEO®, a proprietary, pre-filled, single-use needle-free auto-injector. This platform is designed to enable patients or untrained caregivers to rapidly, safely, and reliably administer emergency treatments. Crossject's product pipeline targets critical conditions such as epileptic seizures, acute adrenal crisis, and severe allergic reactions (anaphylaxis), aiming to improve patient outcomes by simplifying drug delivery in urgent scenarios.

Recent filings

Filing Released Lang Actions
RAPPORT FINANCIER 2025
Annual Report
2026-04-30 French
MISE A DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025
Annual Report FY 2025
2026-04-30 French
MISE A DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025
Annual Report FY 2025
2026-04-30 French
CROSSJECT nomme Lionel SELTZ au poste de Directeur Administratif et Financier
Board/Management Information Classification · 1% confidence The text is a corporate press release announcing the appointment of Lionel SELTZ as the new Chief Financial Officer, which is clearly a change in senior management. This fits the Board/Management Information category.
2026-03-25 French
CROSSJECT appoints Lionel Seltz as Chief Financial Officer
Board/Management Information Classification · 1% confidence The document is a press release announcing the appointment of a new Chief Financial Officer, which is a change in senior management. This clearly fits the Board/Management Information category (MANG).
2026-03-25 English
CROSSJECT publishes its 2025 financial results and confirms the strengthening of its operational, industrial and financial trajectory
Earnings Release Classification · 1% confidence The document is a press release titled “CROSSJECT publishes its 2025 financial results,” providing narrative commentary on the full-year results (revenues, operating loss, net loss, cash position) and including appended detailed financial statements (income statement, balance sheet, cash flow). It is an initial public announcement of the company’s annual results rather than the full audited Annual Report or a regulatory filing notice. This fits the definition of an Earnings Release (ER). FY 2025
2026-03-25 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.